• Larry F Chu, Tom Rico, Erika Cornell, Hannah Obasi, Ellen M Encisco, Haley Vertelney, Jamison G Gamble, Clayton W Crawford, John Sun, Anna Clemenson, Matthew J Erlendson, Robin Okada, Ian Carroll, and J David Clark.
• Department of Anesthesia, Stanford University School of Medicine, 300 Pasteur Drive, Grant Building Room S268C, Stanford, CA, 94305, United States. Electronic address: lchu@stanford.edu.
• Drug Alcohol Depend. 2018 Feb 1; 183: 176-183.

ObjectivesIn this study, we investigated the co-administration of ondansetron with morphine, and whether it could prevent the development of physical dependence in patients taking opioids for the treatment of chronic pain.MethodsA total of 48 chronic back pain patients (N = 48) participated in this double-blinded, placebo-controlled, randomized study. Patients were titrated onto sustained-release oral morphine and randomized to take 8 mg ondansetron or placebo three times daily concurrently with morphine during the 30-day titration. Following titration, patients underwent Naloxone induced opioid withdrawal. Opioid withdrawal signs and symptoms were then assessed by a blinded research assistant (objective opioid withdrawal score: OOWS) and by the research participant (subjective opioid withdrawal score: SOWS).ResultsWe observed clinically significant signs of naloxone-precipitated opioid withdrawal in all participants (ΔOOWS = 4.3 ± 2.4, p < 0.0001; ΔSOWS = 14.1 ± 11.7, p < 0.0001), however no significant differences in withdrawal scores were detected between treatment groups.ConclusionWe hypothesized that ondansetron would prevent the development of physical dependence in human subjects when co-administered with opioids, but found no difference in naloxone-precipitated opioid withdrawal scores between ondansetron and placebo treatment groups. These results suggest that further studies are needed to determine if 5HT3 receptor antagonists are useful in preventing opioid physical dependence.Copyright © 2017 Elsevier B.V. All rights reserved.

35 keywords...

hide…